background
secondari
inhal
medic
aerosol
signific
occup
hazard
clinic
homecar
set
exposur
fugit
emiss
gener
aerosol
therapi
increas
risk
unnecessari
inhal
medic
well
toxic
side
effect
method
studi
examin
fugitivelyemit
aerosol
emiss
nebulis
albuterol
sulphat
tracer
aerosol
use
two
commerci
avail
nebulis
combin
open
valv
facemask
use
mouthpiec
without
filter
exhal
port
combin
connect
breath
simul
simul
adult
breath
inhal
dose
residu
mass
quantifi
use
uv
spectrophotometri
timevari
fugitivelyemit
aerosol
concentr
size
distribut
nebulis
record
use
aerodynam
particl
sizer
two
distanc
rel
simul
patient
differ
aerosol
concentr
size
distribut
observ
depend
interfac
result
within
nebulis
facemask
combin
highest
timeaverag
fugitivelyemit
aerosol
concentr
valu
mg
record
placement
filter
exhal
port
mouthpiec
yield
lowest
record
concentr
mass
median
aerodynam
diamet
fugitivelyemit
aerosol
record
lower
initi
gener
medic
aerosol
rang
conclus
result
highlight
potenti
secondari
inhal
exhal
aerosol
commerci
avail
nebulis
facemaskmouthpiec
combin
result
aid
develop
approach
inform
polici
best
practic
risk
mitig
fugit
emiss
aerosol
therapi
mainstay
drug
administr
home
clinic
set
acut
longterm
treatment
varieti
aerosol
gener
technolog
deliv
drug
lung
patient
interfac
across
full
rang
neonat
adult
patient
size
distribut
gener
medic
aerosol
typic
releas
indoor
particl
remain
airborn
time
rang
minut
hour
exhal
aerosol
aerosol
may
inhal
deposit
airway
surfac
addit
aerosol
gener
nebulis
inspiratori
phase
releas
could
inhal
exhal
fraction
regard
fugit
dose
notabl
consid
possibl
unintend
bystand
inhal
includ
caregiv
famili
member
exposur
fugit
emiss
gener
aerosol
therapi
increas
risk
unnecessari
inhal
medic
well
toxic
side
effect
howev
fundament
exhal
mechan
previouslyinh
aerosol
droplet
aerosol
therapi
well
describ
secondari
inhal
medic
aerosol
risk
factor
caregiv
bystand
highlight
signific
occup
hazard
clinic
homecar
set
studi
rais
concern
surround
potenti
secondari
exposur
healthcar
worker
aerosolis
pentamidin
sustain
releas
lipid
inhal
target
slit
cisplatin
adenoassoci
serotyp
vector
contain
cystic
fibrosi
transmembran
conduct
regul
complementari
dna
tgaavcf
ribavirin
respiratori
therapist
increas
risk
develop
asthma
enter
profess
may
partial
explain
occup
exposur
rang
aerosolis
substanc
addit
grow
global
concern
acquir
antimicrobi
resist
ami
peopl
develop
multidrug
resist
tuberculosi
year
use
nebulis
antibiot
could
potenti
contribut
ami
among
longterm
caregiv
may
inhal
fugit
antibioticladen
aerosol
sever
acut
respiratori
syndrom
sar
outbreak
anecdot
report
highlight
infect
person
receiv
aerosol
therapi
may
facilit
transmiss
sar
certain
circumst
clinic
guidelin
recommend
gener
aerosol
avoid
includ
use
noninvas
ventil
highflow
oxygen
lmin
nebulis
invitro
studi
examin
mechan
ventil
patient
withwithout
expiratori
filter
report
drug
deposit
exhaust
port
without
filter
exceed
filter
case
addit
conclud
greater
nomin
dose
could
becom
secondhand
medic
aerosol
highdefinit
video
imag
studi
use
previouslyinh
salin
aerosol
smoke
particl
estim
dispers
distanc
exhal
air
variou
system
exhal
droplet
observ
exit
side
vent
facemask
substanti
exposur
exhal
air
report
occur
within
nebulis
airflow
lung
function
interfac
type
report
impact
upon
dispers
distanc
limit
visualis
approach
visibl
boundari
exhal
flow
could
use
guid
real
behaviour
droplet
exhal
air
respiratori
therapi
context
secondari
exposur
pathway
wide
understood
limit
evid
exist
explain
fugit
emiss
date
research
primarili
focus
infect
control
model
current
studi
aim
enhanc
understand
secondari
exposur
aerosol
emit
respiratori
therapi
commonlyus
equip
studi
examin
potenti
secondari
caregiverbystand
exposur
domest
clinic
caregiv
set
examin
key
factor
influenc
secondari
exposur
caregiv
posit
devic
type
design
oper
featur
two
preval
nebulis
technolog
assess
regard
emiss
exhal
aerosol
vibrat
mesh
vmn
use
combin
aerosol
chamber
aerogen
soloultra
aerogen
galway
ireland
jet
jn
cirru
intersurg
wokingham
unit
kingdom
clinic
use
today
studi
incorpor
two
noninvas
ventil
interfac
facemask
mouthpiec
combin
commerci
avail
aerosol
gener
vmn
use
valv
facemask
jn
use
open
facemask
mouthpiec
scenario
unfilt
mouthpiec
filter
mouthpiec
use
setup
filter
mouthpiec
refer
filter
place
exhal
port
unfilt
mouthpiec
refer
case
filter
place
exhal
port
replic
ideal
condit
achiev
patient
use
interfac
correctli
mask
glu
plastic
sheet
avoid
leak
mouthpiec
attach
use
custom
fixtur
supplement
ga
flow
rate
lmin
use
vmn
manufacturerprescrib
lmin
use
jn
nebulis
individu
assess
simul
real
use
condit
laboratori
room
volum
three
intern
door
extern
door
window
room
mechan
ventil
air
exchang
rate
h
ambient
temperatur
rel
humid
test
room
typic
c
respect
test
period
aerosol
generatorinterfac
combin
connect
breath
simul
asl
ingmar
medic
pittsburgh
pa
usa
via
absolut
filter
respirgard
ii
baxter
dublin
ireland
simul
adult
breath
use
breath
rate
bpm
tidal
volum
ml
inspiratori
expiratori
e
ratio
result
institut
review
board
requir
studi
nomin
dose
ml
mg
albuterol
sulphat
ventolin
mgml
gsk
cork
ireland
nebulis
test
run
aerosol
deliveri
perform
evalu
characteris
inhal
dose
say
drug
deliv
patient
determin
inhal
dose
aerosol
generatorinterfac
combin
attach
absolut
collect
filter
figur
albuterol
commonli
nebulis
medic
also
formul
use
character
aerosol
drug
deliveri
system
specifi
use
tracer
aerosol
studi
albuterol
elut
filter
nebulis
compon
use
wash
buffer
albuterol
mass
express
fraction
nomin
dose
end
run
extract
quantifi
use
uv
spectrophotometri
biochrom
uv
vi
cambridg
uk
nm
interpol
standard
curv
albuterol
sulphat
exhal
dose
drug
exhal
spontan
breath
patient
also
characteris
mouthpiec
test
place
collect
filter
exhal
port
nebulisermouthpiec
combin
figur
addit
residu
mass
drug
avail
nebulis
remain
devic
report
vmn
jn
devic
test
carri
triplic
pharmaceut
x
peer
review
flow
rate
lmin
use
vmn
manufacturerprescrib
lmin
use
jn
nebulis
individu
assess
simul
real
use
condit
laboratori
room
volum
three
intern
door
extern
door
window
room
mechan
ventil
air
exchang
rate
h
ambient
temperatur
rel
humid
test
room
typic
respect
test
period
aerosol
generatorinterfac
combin
connect
breath
simul
asl
ingmar
medic
pittsburgh
pa
usa
via
absolut
filter
respirgard
ii
baxter
dublin
ireland
simul
adult
breath
use
breath
rate
bpm
tidal
volum
ml
inspiratori
expiratori
e
ratio
result
institut
review
board
requir
studi
nomin
dose
ml
mg
albuterol
sulphat
ventolin
mgml
gsk
cork
ireland
nebulis
test
run
aerosol
deliveri
perform
evalu
characteris
inhal
dose
say
drug
deliv
patient
determin
inhal
dose
aerosol
gener
interfac
combin
attach
absolut
collect
filter
figur
albuterol
commonli
nebulis
medic
also
formul
use
character
aerosol
drug
deliveri
system
specifi
use
tracer
aerosol
studi
albuterol
elut
filter
nebulis
compon
use
wash
buffer
albuterol
mass
express
fraction
nomin
dose
end
run
extract
quantifi
use
uv
spectrophotometri
biochrom
uv
vi
cambridg
uk
nm
interpol
standard
curv
albuterol
sulphat
exhal
dose
drug
exhal
spontan
breath
patient
also
characteris
mouthpiec
test
place
collect
filter
exhal
port
nebulisermouthpiec
combin
figur
addit
residu
mass
drug
avail
nebulis
remain
devic
report
vmn
jn
devic
test
carri
triplic
primari
aerosol
monitor
instrument
use
studi
aerodynam
particl
sizer
ap
ap
model
tsi
inc
st
paul
mn
usa
measur
aerosol
size
distribut
throughout
experi
aerosol
concentr
size
distribut
aerosol
continu
measur
real
time
use
two
apss
locat
respect
distanc
simul
patient
distanc
chosen
basi
approxim
one
arm
length
away
simul
exampl
caregiv
hold
primari
aerosol
monitor
instrument
use
studi
aerodynam
particl
sizer
ap
ap
model
tsi
inc
st
paul
mn
usa
measur
aerosol
size
distribut
throughout
experi
aerosol
concentr
size
distribut
aerosol
continu
measur
real
time
use
two
apss
locat
respect
distanc
simul
patient
distanc
chosen
basi
approxim
one
arm
length
away
simul
exampl
caregiv
hold
nebuliserfacemask
patient
face
distanc
chosen
basi
approxim
distanc
bed
primari
care
centr
simul
patient
situat
bed
next
patient
receiv
aerosol
therapi
baselin
level
aerosol
establish
room
prenebulis
nebulis
initi
apss
record
data
min
interv
durat
min
suffici
nebulis
entir
dose
period
aerosol
decay
postdos
test
carri
concurr
aerosol
dose
distribut
test
describ
statist
packag
iibm
spss
statist
ibm
corp
armonk
ny
usa
use
analys
data
summari
descript
statist
perform
aerosol
concentr
data
express
mean
minimum
maximum
collect
filter
analys
term
inhal
dose
exhal
dose
residu
mass
result
summaris
tabl
residu
mass
inhal
dose
vari
depend
nebulis
type
result
within
nebulis
group
substanti
equival
prior
nebulis
mean
standard
deviat
ambient
concentr
mg
tabl
confirm
fugit
emiss
record
nebulis
event
facemask
unfilt
mouthpiec
combin
record
increas
aerosol
concentr
use
vmnfilter
mouthpiec
increas
aerosol
concentr
record
jnfilter
mouthpiec
seen
tabl
use
vmnunfilt
mouthpiec
jnunfilt
mouthpiec
combin
result
reduc
exhal
aerosol
concentr
compar
correspond
facemask
tempor
variat
aerosol
concentr
use
jet
nebulis
result
larger
differ
two
ap
read
open
facemask
combin
compar
configur
largest
variat
aerosol
concentr
two
apss
occur
nebulis
period
case
less
averag
differ
two
set
measur
final
min
nebulis
indic
diffus
fugit
emiss
throughout
room
tabl
summaris
averag
mmad
period
record
ap
metr
facemaskmouthpiec
notic
shift
mmad
nebulis
event
use
facemaskmouthpiec
compar
initiallygener
aerosol
tabl
thirtyminut
averag
aerosol
concentr
nebulis
event
use
differ
facemask
mouthpiec
mean
standard
deviat
three
event
reduc
size
restrict
open
area
valv
facemask
assum
result
exhal
aerosol
lower
mmad
exhal
open
facemask
configur
percentag
origin
drug
could
potenti
inhal
caregiv
bystand
estim
averag
jnopen
facemask
timeseri
data
select
exhibit
highest
level
fugit
emiss
fiveminut
baselin
averag
ambient
aerosol
concentr
subtract
timeseri
data
focu
sole
fugit
emiss
shortterm
exposur
valu
inhal
repres
light
activ
caregiv
min
sedentari
activ
bystand
min
age
rang
year
old
calcul
caregiv
bystand
assum
respect
distanc
patient
scenario
caregiv
bystand
estim
expos
origin
nomin
drug
dose
place
nebulis
respect
studi
highlight
potenti
secondari
inhal
exposur
fugit
emiss
caregiv
bystand
standard
nebulis
treatment
studi
provid
realtim
monitor
data
sizeresolv
indoor
aerosol
concentr
aerosol
generatornoninvas
ventil
interfac
connect
breath
simul
use
replic
adult
breath
pattern
current
approach
explicitli
remov
ambient
aerosol
contribut
data
evid
observ
chang
aerosol
concentr
due
aerosol
nebulis
event
sever
factor
influenc
inhal
dose
like
affect
quantiti
releas
aerosol
environment
factor
includ
room
dimens
layout
air
turbul
ventil
temperatur
also
affect
releas
aerosol
distribut
current
observ
therefor
extrapol
caution
nevertheless
note
studi
provid
compel
evid
caregiv
bystand
receiv
inadvert
drug
dose
intend
patient
note
respect
inhal
exposur
caregiv
bystand
base
fugit
emiss
standard
treatment
use
standard
compressordriven
jet
nebulis
howev
common
higher
nomin
dose
administ
mgh
period
rang
h
aerosolis
ribavirin
also
report
nebulis
rate
g
h
per
day
caregivermed
practition
may
work
hospit
sever
patient
may
receiv
aerosol
therapi
throughout
day
mani
daysweek
sever
year
therefor
potenti
chronic
low
dose
occup
exposur
concern
studi
medic
nebulis
gener
aerosol
size
distribut
within
respir
rang
howev
mmad
fugit
emiss
rang
across
nebulis
combin
indic
consider
smaller
aerosol
size
fraction
releas
origin
gener
nebulis
signific
find
lower
size
fraction
remain
airborn
extend
period
time
vmn
combin
reduc
fugit
emiss
compar
jn
like
due
combin
lower
airflow
valv
system
vmn
case
unfilt
mouthpiec
reduc
fugit
emiss
compar
facemask
sinc
appreci
chang
residu
drug
analysi
differ
facemaskmouthpiec
combin
conclud
mouthpiec
shape
size
influenc
inerti
impact
deposit
filter
mouthpiec
combin
observ
fugit
emiss
jnfilter
mouthpiec
combin
compar
vmn
possibl
higher
drive
forc
requir
normal
oper
jnmouthpiec
caus
addit
system
pressur
allow
aerosol
escap
custom
fixtur
howev
unclear
would
replic
human
patient
earlier
imag
studi
observ
emit
droplet
respiratori
filter
place
exhal
port
research
show
attach
exhal
filter
nebulis
effect
captur
exhal
aerosol
droplet
facemask
design
may
also
contribut
necess
compressordriven
jet
nebulis
must
oper
open
facemask
ie
one
without
valv
combin
continu
posit
pressur
air
flow
act
forc
aerosol
devic
environ
throughout
inhal
exhal
cycl
breath
case
vibrat
mesh
nebulis
drive
air
flow
requir
aerosol
gener
valv
system
devic
describ
aid
build
reservoir
aerosol
within
patient
interfac
avail
next
breath
previou
studi
drug
distribut
inhal
filter
exhal
filter
ventil
tube
medic
reservoir
quantifi
vmn
jn
comparison
possibl
studi
residu
drug
vmn
compar
mean
valu
interfac
current
studi
residu
jn
compar
present
studi
albeit
differ
jn
inhal
filter
record
compar
current
studi
vmn
jn
respect
respiratori
therapi
context
secondari
exposur
pathway
wide
understood
adult
breath
pattern
combin
facemaskmouthpiec
use
replic
standard
nebulis
treatment
monitor
consequ
releas
fugit
emiss
best
author
knowledg
first
studi
quantifi
timeseri
aerosol
concentr
size
distribut
fugit
emiss
result
standard
nebulis
treatment
find
confirm
potenti
exposur
risk
caregiv
bystand
medic
aerosol
highlight
variat
patient
interfac
facemask
mouthpiec
aerosol
gener
vmn
jn
influenc
fugitivelyemit
aerosol
concentr
purpos
studi
aid
develop
approach
healthcar
organis
inform
polici
best
practic
risk
mitig
fugit
emiss
futur
studi
focu
investig
factor
reallif
clinic
scenario
